SAR-442501

N/A

Report date: 2025/04/25 20:01:23

Base Information

Drug NameSAR-442501
Drug Alias NameSAR-442501
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionFibroblast growth factor receptor 3 antagonists
TargetsFibroblast growth factor receptor 3
Therapy Area/IndicationsOsteochondrodysplasiasAchondroplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesItaly +[9] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesSanofi
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSanofi
Inactive CompaniesSanofi-Aventis Recherche & DeveloppementSanofi (China) Investment Co Ltd
Active IndicationsOsteochondrodysplasiasAchondroplasia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A